跳至主要内容
临床试验/NCT05270863
NCT05270863已完成3 期

Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia

Visus Therapeutics1 个研究点 分布在 1 个国家目标入组 182 人开始时间: 2022年3月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
182
试验地点
1
主要终点
Proportion of Subjects With >=15 Letter Gain Without >=5 Letter Loss in Near Visual Acuity

研究概览

简要总结

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

详细描述

Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
45 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female in good general health
  • Must have presbyopia

排除标准

  • History of allergic reaction to the study drug or any of its components
  • Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results

研究组 & 干预措施

BRIMOCHOL™ PF

Experimental

A single drop in each eye at a visit.

干预措施: BRIMOCHOL™ PF (Drug)

Carbachol PF

Active Comparator

A single drop in each eye at a visit.

干预措施: Carbachol PF (Drug)

Brimonidine tartrate

Active Comparator

A single drop in each eye at a visit.

干预措施: Brimonidine tartrate (Drug)

结局指标

主要结局

Proportion of Subjects With >=15 Letter Gain Without >=5 Letter Loss in Near Visual Acuity

时间窗: Day 1 Hour 1

Primary endpoint measure at hour 1 post-dose at study visit

次要结局

未报告次要终点

研究者

发起方
Visus Therapeutics
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验